Novavax's COVID-19 Vaccine, Flu Shot Co-administration Preserved Efficacy, Likely 'Viable Strategy,' Company Says

  • Novavax Inc NVAX announced its experimental COVID-19 vaccine remained effective when coadministered with an approved flu shot.
  • Researchers are interested in studying coadministration and the associated safety & efficacy of giving multiple vaccines to a person during one visit to ease logistics and help patients catch up on missed vaccinations, especially amid the pandemic.
  • The company released the results from a sub-study it conducted as part of its late-stage clinical trial of NVX-CoV2373 in the U.K.
  • The 431 participants enrolled in the sub-study received an approved seasonal influenza vaccine, with about half the participants administered NVX-CoV2373, while the rest received a placebo.
  • The company said vaccine efficacy was 87.5% compared to 89.8% in the main study.
  • Despite the "modest decrease," antibodies against the spike protein were reported as over three-fold higher than levels found in blood samples of people who received both vaccines.
  • The news comes hours after Novavax announced that its protein-based COVID-19 vaccine was found to be over 90% effective overall and offered 100% protection against moderate and severe disease in a Phase 3 trial.
  • Price Action: NVAX shares are up 2.8% at $213.5 during the premarket session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareGeneralBriefsCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!